Boston Scientific is growing its urology portfolio with a $3.7 billion deal to acquire Axonics, makers of neurostimulation therapies for urinary and fecal incontinence. Currently a chief competitor in ...
Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat ...
The Federal Trade Commission (FTC) is taking a closer look at Boston Scientific’s $3.7 billion proposal to acquire neuromodulation developer Axonics, a move that could push back the closing of the ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results